Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Ru Zhou, Deepak Dalvie et al.|Journal of Medicinal Chemistry|2016Cited by 93
Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Jennifer Lafontaine, Douglas C. Behenna et al.|Journal of Medicinal Chemistry|2017Cited by 90
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, John C. Kath, Suvi T. M. Orr et al.|Journal of Medicinal Chemistry|2020Cited by 40
CCDC 1541947: Experimental Crystal Structure DeterminationSimon Planken, Jennifer Lafontaine, Douglas C. Behenna et al.|The Cambridge Structural Database|2017Cited by 0